Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Pacific Biosciences of California's 3-Year RORE % for the quarter that ended in Mar. 2026 was -14.03%.
MEX:PACB's 3-Year RORE % is ranked worse than 62.79% of 782
companies
in the Medical Devices & Instruments industry
Industry Median: -4.17
vs MEX:PACB: -14.03
Pacific Biosciences of California (MEX:PACB) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Pacific Biosciences of California 3-Year RORE % Related Terms
Pacific Biosciences of California 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacific Biosciences of California 3-Year RORE % Chart
MEX:PACB vs KIDS, MOBI, SI: 3-Year RORE % Comparison
For the Medical Devices subindustry, Pacific Biosciences of California's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacific Biosciences of California 3-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pacific Biosciences of California's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Pacific Biosciences of California's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Pacific Biosciences of California (MEX:PACB) has a 3-Year RORE % of -14.03 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Pacific Biosciences of California and its competitors. According to the industry distribution chart, Pacific Biosciences of California ranks #491 out of 782 companies in the Medical Devices & Instruments industry, placing it in the top 62.8%.
Is Pacific Biosciences of California's 3-Year RORE % too high?
Pacific Biosciences of California's current 3-Year RORE % is -14.03. Based on the distribution chart, Pacific Biosciences of California ranks #491 out of 782 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Pacific Biosciences of California has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Pacific Biosciences of California's 3-Year RORE % compare to KIDS and MOBI?
According to the Medical Devices & Instruments industry distribution chart, Pacific Biosciences of California ranks #491 out of 782 companies for 3-Year RORE %. This places Pacific Biosciences of California in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Pacific Biosciences of California and its competitors. Pacific Biosciences of California's current 3-Year RORE % is -14.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Biosciences of California stock overvalued right now?
Pacific Biosciences of California (MEX:PACB) has a current 3-Year RORE % of -14.03. The stock's GF Value™ is MXN27.00, compared to a current price of MXN27.50 — trading 1.9% above its estimated fair value. The current 3-Year RORE % is -14.03. Pacific Biosciences of California's overall GF Score™ is 53/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Pacific Biosciences of California (MEX:PACB), the current 3-Year RORE % is -14.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacific Biosciences of California (MEX:PACB) Overvalued in 2026?
Based on GuruFocus' analysis, Pacific Biosciences of California stock appears to be overvalued.
The current stock price of MXN27.50 is trading 1.9% above its estimated GF Value™ of MXN27.00.
Key valuation signals for MEX:PACB:
3-Year RORE %: -14.03
GF Value™: MXN27.00 vs. price of MXN27.50 (1.9% above fair value)
No single metric tells the full story. See the MEX:PACB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacific Biosciences of California Business Description
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
53GF Score
Get the complete analysis for MEX:PACB
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:PACB has been successfully added to your 
